The future prospects for IRLAB Therapeutics AB's mesdopetam, and the firm's partnership with Ipsen SA, are looking shakier after the investigational Parkinson's disease drug missed its primary goal in a mid-stage study.
Irlab Parkinson's Pact With Ipsen Up In The Air
Setback For Mesdopetam In Mid-Stage Study
The Swedish firm’s Parkinson's disease drug has failed to hit its primary endpoint in a Phase IIb study but Irlab believes that positive results on secondary goals merit further development of mesdopetam.
